Plum Alley

Plum Alley

Plum Alley team

Plum Alley makes early stage investments in companies at the leading edge of the climate, health, and sustainability economies.

Firm overview

Plum Alley is an early-stage venture fund investing at the intersection of deep tech and frontier healthcare. The firm has developed a strong reputation for investing in category-defining companies founded by women scientists and technologists. Investors Deborah Jackson, Avantika Daing, and Andrea Turner Moffitt bring unique and complementary experiences to Plum Alley as entrepreneurs, operators, investors, and capital fundraising experts. On the Plum Alley team, Deborah is “The Futurist,” for her feverish pursuit to identify the latest trends in technology and healthcare, and for her reputation for seeing around corners. She has been an early-stage investor for nearly two decades and is well known for founding Women Innovate Mobile, an accelerator for women in mobile tech. Avantika is “The Operator,” with 25 years of operating experience spanning biotech, consumer healthcare, and technology. Avantika helped scale multiple teams and businesses to millions in revenue and billions in valuation, including a successful IPO and multiple M&A exits. She also advised companies backed by the a16z and Omidyar portfolios. Andrea is “The Analyst”: She brings two decades of experience investing and capital raising, with a focus on enterprise technology, SaaS, energy, and infrastructure. Andrea has invested and raised billions of dollars for high-growth companies, and also founded a fintech content platform. The Plum Alley team has been investing for nearly five years together, and has demonstrated an uncommon ability to source top deals leading to outsized returns and impact.

Firm strategy

Plum Alley invests in advanced technologies and medical breakthroughs at the leading edge of the health, climate, sustainable industry, and equitable economies. The firm specifically invests in companies bringing innovative solutions—such as sensors, computer vision, AI/ML, automation, predictive diagnostics, synthetic biology, and regenerative medicine—to large, high-value markets at scale. Plum Alley’s focus is Series A stage, with select investments at the Series B stage. The investment team works closely with their portfolio founders, often serving as the first call ahead of a board meeting. They provide extensive value-add around scaling, commercialization, and capital raising strategies. Plum Alley also taps its diverse network of investors who are operators, executives, and public company board members, to provide entrepreneurs with additional value. The firm also has a powerful co-investment strategy and a strong reputation for securing strategic follow-on investors for portfolio companies. 

Why we invested

Plum Alley shares our mission to not only accelerate the success of diverse founders, but also to expand access to more investors—especially women and minorities, who have much value to add to the venture asset class. As we got to know Plum Alley, we were struck by their combined expertise across the go-to-market, capital raising, and investing domains. We also valued Plum Alley’s focus on investing not only for outsized returns, but also in companies creating generational impact. 

 

DISCLOSURE: This publication contains general information only and eShares, Inc. d/b/a Carta, Inc. (“Carta”). Carta is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services nor should it be used as a basis for any decision or action that may affect your business or interests. Before making any decision or taking any action that may affect your business or interests, you should consult a qualified professional advisor. This communication is not intended as a recommendation, offer or solicitation for the purchase or sale of any security. Carta does not assume any liability for reliance on the information provided herein. All product names, logos, and brands are property of their respective owners in the U.S. and other countries, and are used for identification purposes only. Use of these names, logos, and brands does not imply affiliation or endorsement.
©2022 eShares, Inc. d/b/a Carta, Inc. All rights reserved. Reproduction prohibited.